Rib-X Pharmaceuticals Lands Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=46f40007-2620-4688-9594-89a1101cb132&Preview=1 -
Date
11/29/2012 -
Company Name
Rib-X Pharmaceuticals -
Mailing Address
300 George Street New Haven, CT 06511 -
Company Description
Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis. -
Website
http://www.rib-x.com -
Transaction Type
Venture Equity -
Transaction Amount
Undisclosed -
Transaction Round
Series B -
Proceeds Purposes
With this financing, we plan to initiate the Phase 3 program for delafloxacin, which performed successfully in Phase 2b against all endpoints, including the new objective endpoints issued by the FDA. -
M&A Terms
-
Venture Investor
Vatera Healthcare Partners -
Venture Investor
Warburg Pincus -
Venture Investor
ABS Ventures -
Venture Investor
Undisclosed
